Austria's Intercell is buying Iomai for $189 million in cash and stock. The deal will add Iomai's patch to prevent traveler's diarrhea and an adjuvant for bird flu vaccine that has produced impressive data. Report
Austria's Intercell is buying Iomai for $189 million in cash and stock. The deal will add Iomai's patch to prevent traveler's diarrhea and an adjuvant for bird flu vaccine that has produced impressive data. Report